A randomized, double-blind, placebo-controlled, multicenter study evaluated 217 adults aged 18 to 66 years with acute bronchitis. Participants in the active arm (n=108) received Pelargonium sidoides, 30 drops (1.5 mL) or placebo 3 times daily, for 7 days. Changes in bronchitis severity score (BSS: cough, sputum, rales/rhonchi, chest pain at cough, dyspnea) were assessed. At the end of treatment, the BSS decreased by 7.6 points in the active treatment group and by 5.3 points in the placebo group. The following signs and symptoms were reported as better in the Pelargonium sidoides group over placebo: cough, sputum, rales/rhonchi, chest pain at cough, dyspnea, hoarseness, fatigue, fever, headache, and limb pain. A higher rate of minor adverse effects were reported in the placebo group compared to the treatment group and no serious adverse events occurred. (3)
